These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34400802)

  • 1. An urgent call to raise the bar in oncology.
    Schnog JB; Samson MJ; Gans ROB; Duits AJ
    Br J Cancer; 2021 Nov; 125(11):1477-1485. PubMed ID: 34400802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015.
    Grössmann N; Robausch M; Rothschedl E; Wild C; Simon J
    Eur J Cancer; 2020 Apr; 129():23-31. PubMed ID: 32120272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 4. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 5. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
    Ludwig WD; Schildmann J
    Onkologie; 2011; 34 Suppl 1():6-10. PubMed ID: 21389762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 8. Seeking value as cancer drug costs soar.
    Bender E
    Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using cancer registries to supplement clinical trial data and inform regulatory decision.
    da Costa FA; da Costa Miranda A
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1319-1321. PubMed ID: 31788909
    [No Abstract]   [Full Text] [Related]  

  • 10. How to create successful alternative payment models in oncology.
    Miller HD
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP160-SP163. PubMed ID: 28665673
    [No Abstract]   [Full Text] [Related]  

  • 11. The economic crisis and cancer chemotherapy: the role of the oncologist.
    Rescigno P; Imbevaro S; Jirillo A
    Tumori; 2012; 98(4):532-3. PubMed ID: 23052172
    [No Abstract]   [Full Text] [Related]  

  • 12. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 13. Can cancer care lead the way toward a value-based future?
    Macmillan K
    Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP377-SP378. PubMed ID: 31860249
    [No Abstract]   [Full Text] [Related]  

  • 14. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 15. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario.
    Naipaul RD; Mercer RE; Chan KKW; Yeung L; Forbes L; Gavura S
    Curr Oncol; 2021 Feb; 28(2):1056-1066. PubMed ID: 33652898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. US Cancer Care System Ill-Equipped to Deliver New Advances to Patients.
    Rappaport M
    J Oncol Pract; 2016 May; 12(5):397. PubMed ID: 27170686
    [No Abstract]   [Full Text] [Related]  

  • 20. [Let's go forward, but wisely…].
    Di Maio M
    Recenti Prog Med; 2017 Dec; 108(12):494-496. PubMed ID: 29297896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.